Evidence map›Paper›PMID 34696543›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer].

Na Li, Yanjun Xu, Yun Fan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Na LiWenzhou Medical University, Wenzhou 325035, China.
Yanjun XuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of 
Sciences, Hangzhou 310022, China.
Yun FanInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of 
Sciences, Hangzhou 310022, China.
Cancer Hospital of Chinese Academy of Medical Sciences · CNWenzhou Medical University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC.
.

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsHumansMutationProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-rafBRAFImmunotherapyLung neoplasmsTargeted therapy

Identifiers

PMID34696543
PMCPMC8560979
OpenAlexW3211280182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.